| Nombre del producto |
adriamicinol |
| Sinónimos |
13-dihidrodoxorrubicina; 10-((3-amino-2,3,6-tridesoxi-alfa-L-lyxo-hexopiranosil)oxi)-8-(1,2-dihidroxietil)-7,8,9,10-tetrahidro-6,8,11-trihidroxi-1-metoxi-5,12-naftanoediona; 5,12-Nafthacenediona, 10-((3-amino-2,3,6-tridesoxi-alfa-L-lyxo-hexopiranosil)oxi)-8-(1,2-dihidroxietil)-7,8,9,10-tetrahidro-6,8,11-trihidroxi-1-metoxi-; 3-(1,2-dihidroxietil)-3,5,12-trihidroxi-10-metoxi-6,11-dioxo-1,2,3,4,6,11-hexahidrotetracen-1-il 3-amino-2,3,6-tridesoxi-L-lixo-hexopiranosio; (1S,3S)-3-[(1S)-1,2-dihidroxietil]-3,5,12-trihidroxi-10-metoxi-6,11-dioxo-1,2,3,4,6,11-clorhidrato de hexahidrotetracen-1-il 3-amino-2,3,6-tridesoxi-alfa-L-lyxo-hexopiranósido (1:1) |
| Nombre en inglés |
adriamycinol;13-Dihydrodoxorubicin; 10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-8-(1,2-dihydroxyethyl)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-8-(1,2-dihydroxyethyl)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-; 3-(1,2-dihydroxyethyl)-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-L-lyxo-hexopyranoside; (1S,3S)-3-[(1S)-1,2-dihydroxyethyl]-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside hydrochloride (1:1) |
| Fórmula molecular |
C27H32ClNO11 |
| Peso Molecular |
581.9961 |
| InChI |
InChI=1/C27H31NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15-17,22,29-31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,16-,17-,22+,27-;/m0./s1 |
| Número de registro CAS |
141434-67-5 |
| Estructura Molecular |
|
| Punto de ebullición |
828.7°C at 760 mmHg |
| Punto de inflamación |
455°C |
| Presión de vapor |
4.26E-29mmHg at 25°C |
| Símbolos de Peligro |
|
| Códigos de Riesgos |
|
| Descripción de Seguridad |
|
|
